Login to Your Account



Pharma: Other News To Note


Thursday, August 2, 2012
• Watson Pharmaceuticals Inc., of Parsippany, N.J., said it received approval from the FDA for its abbreviated new drug application for Budesonide Inhalation Suspension 0.25 mg/2mL and 0.5 mg/2mL, the generic equivalent for London-based AstraZeneca plc's Pulmicort Respules.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription